AMGN currently shows a PEG ratio reading of 0.77 as of Jun 22, 2026. Dividing the 23.81 PE ratio by the 31.0% earnings growth rate produces this figure. When benchmarked against the trailing 4-quarter average of 0.39, AMGN's PEG ratio reflects a 96% increase.
A ten years lookback reveals an average PEG ratio of 1.64 for Amgen. Compared to historical data, AMGN's 0.77 PEG ratio represents a decrease of 53%. The ten years high came in the Dec 2019 quarter at 9.3, reflecting peak valuation relative to growth. The bottom was reached in the Dec 2018 quarter at 0.04, suggesting favorable value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.26 | 22.84 | 88.1% |
| 2024 | N/A | 34.2 | -39.3% |
| 2023 | 7.4 | 22.93 | 3.1% |
| 2022 | 1.21 | 21.56 | 17.8% |
| 2021 | N/A | 21.76 | -16.6% |
| 2020 | N/A | 18.54 | -4.3% |
| 2019 | 9.3 | 18.6 | 2% |
| 2018 | 0.04 | 15.33 | 368.6% |
| 2017 | N/A | 64.17 | -73.7% |
| 2016 | 1.11 | 14.17 | 12.8% |
| 2015 | 0.51 | 17.74 | 34.6% |
| 2014 | 33.47 | 23.43 | 0.7% |
| 2013 | 0.83 | 16.9 | 20.3% |
| 2012 | 0.41 | 15.37 | 37.8% |
| 2011 | N/A | 15.78 | -15.6% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.78 | 24.3 | 31% |
| Dec 2025 | 0.26 | 22.84 | 88.1% |
| Sep 2025 | 0.33 | 21.66 | 65.1% |
| Jun 2025 | 0.2 | 22.66 | 110.6% |
| Mar 2025 | 0.49 | 28.19 | 57% |
| Dec 2024 | N/A | 34.2 | -39.3% |
| Sep 2024 | N/A | 40.84 | -44.2% |
| Jun 2024 | N/A | 53.41 | -60.8% |
| Mar 2024 | N/A | 40.39 | -52.5% |
| Dec 2023 | 7.4 | 22.93 | 3.1% |
| Sep 2023 | 1.46 | 18.99 | 13% |
| Jun 2023 | 0.57 | 14.87 | 26.2% |
| Mar 2023 | 0.36 | 16.32 | 45.5% |
| Dec 2022 | 1.21 | 21.56 | 17.8% |
| Sep 2022 | 0.64 | 18 | 28.1% |
Measured against past performance, AMGN's PEG ratio comes in under the 3, 5 and 10-year averages.
With a PEG of 0.77, AMGN ranks higher than the Healthcare sector and its peers average but lower than the industry average. In comparison with the Healthcare sector average of 0.55, Amgen's PEG is 40% higher.
Among its peer stocks LLY and GILD, AMGN's PEG ratio runs higher. Amgen's PEG ratio of 0.77 is above the peer average of 0.3.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ILMN Illumina Inc | 0.15 | $24.42B |
| GILD Gilead Sciences Inc | 0.3 | $155.03B |
| LLY ELI LILLY & Co | 0.3 | $1.04T |
| BMY Bristol Myers Squibb Co | 0.46 | $111.7B |
| AMGN Amgen Inc | 0.77 | $186.05B |
| PFE Pfizer Inc | N/A | $142.94B |
| ABBV AbbVie Inc | N/A | $406.38B |
| BIIB Biogen Inc | N/A | $29.48B |
| JNJ Johnson & Johnson | N/A | $556.77B |
| ABT Abbott Laboratories | N/A | $152.98B |
AMGN has a PEG ratio of 0.77, per Jun 22, 2026 data.
Historical data over a 3-year period puts AMGN's average PEG ratio at 1.44.
Historical data over a 5-year period puts AMGN's average PEG ratio at 1.23.
The Dec 2019 quarter marked the ten years high at 9.3 for AMGN's PEG ratio.
Compared to the 10-year average, AMGN's PEG ratio sits 53% lower.
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jun 22, 2026, Amgen carries a PE ratio of 23.81. Earnings grew at 31.0% over the TTM period ending Mar 2026. Applying the formula, this yields a PEG ratio of 0.77. PEG RATIO(0.77) = PE RATIO(23.81) / EPS GROWTH(31.0%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.